BioAge Labs Q1 net loss $12.9M; cash $335.1M; BGE-102 Phase 1 data expected 2H25

BioAge Labs, Inc.

2025-Q1 EPS reported -$0.36 revenue$1,451,000

Net loss of $12.9M ($0.36 diluted EPS) vs $13.0M loss in Q1 2024; no revenue reported.
R&D expenses $11.1M up from $9.3M YoY on IND-enabling work for BGE-102.
G&A expenses $6.8M up from $3.5M YoY driven by stock-based compensation and D&O insurance.
Cash, equivalents, and marketable securities $335.1M as of March 31, 2025; funds operations through 2029.
Lead candidate BGE-102 (NLRP3 inhibitor) enters IND-enabling studies; initial Phase 1 data anticipated 2H25.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.